Home > Drugs A – Z > Hylan G-F 20 (By injection)

Hylan G-F 20 (By injection)

Treats knee pain caused by osteoarthritis.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Brand names include
Synvisc, Synvisc Hylan GF, Synvisc One
Drug classes About this
Cartilaginous Defect Repair Agent

What works? Research summarized

Evidence reviews

Are intra-articular injections of Hylan G-F 20 efficacious in painful osteoarthritis of the knee? A systematic review and meta-analysis

AIM: To systematically review evidence and perform a meta-analysis of the efficacy of intra-articular (IA) injections of Hylan G-F 20 for the treatment of painful osteoarthritis (OA) of the knee.

Functional improvement with hylan G-F 20 in patients with knee osteoarthritis

The review concluded that hylan G-F 20 (intra-articular hyaluronic acid derivative) relieved pain and improved function in patients with osteoarthritis of the knee. The review's numerous methodological limitations suggest that the authors' conclusions should be interpreted with caution.

Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treament of knee osteoarthritis: a systematic review

This review assessed intra-articular injections of Hylan G-F 20 for the treatment of knee osteoarthritis. The available evidence suggested that Hylan G-F 20 injections decreased pain and improved knee function in the short term. The authors' conclusions are supported by the data presented, but differences between included studies, suggest they should be viewed with caution.

See all (10)

Summaries for consumers

Joint corticosteroid injection for knee osteoarthritis

We searched the literature until 3 February 2015 for studies of the effects on pain, function, quality of life, and safety of intra‐articular (injected into the joint) corticosteroids compared with sham injection or no treatment in people with knee osteoarthritis.

Viscosupplementation for the treatment of osteoarthritis of the knee

Osteoarthritis (OA) is the most common form of chronic arthritis worldwide. Hyaluronan and hylan (HA) products provide opportunity to treat OA in individual knee joints. To evaluate the efficacy, effectiveness and safety of HA products, in knee OA, we have conducted a systematic review using Cochrane methodology. The analyses support the contention that the HA class of products is superior to placebo. There is considerable between‐product, between‐variable and time‐dependent variability in the clinical response. The clinical effect for some products against placebo on some variables at some time points is in the moderate to large effect size range. In general, sample size restrictions preclude any definitive comment on the safety of the HA class of products, however, within the constraints of the trial designs employed, no major safety issues were detected. The analyses suggest that viscosupplements are comparable in efficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events, and that HA products have more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA.

PubMed Health Blog...

read all...